Overall Effectiveness of a Potentiatied 2% Micronized Platelet Pyrithione Zinc Shampoo Among Severe Dandruff/Seborrheic Dermatitis Sufferers INTRODUCTION.

Slides:



Advertisements
Similar presentations
[IPO0663] Study of the effects of cosmetic products to improve the condition of dry skin B.Tyszczuk 1, C. Vincent 1,R. Debowska 1, A. Kaszuba 2, A. Kaszuba.
Advertisements

Infant Colic Drops Relief from digestive discomfort Helps natural sleep CLINICAL STUDIES.
E. A. Jewell-Motz, Ph.D., J. R. Kaczvinsky, Ph.D., K. M. Lammers, M.S., S. Xie, Ph.D., R. M. Osborne, Ph.D P&G Beauty, Cincinnati, Ohio USA Background.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
ARISTOTLE TTR Subanalysis
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Badrul A. Chowdhury, MD, PhD
How to use Clinical Evidence to inform clinical decision making A case presentation using the CE review on acne.
1 OTC Omeprazole Magnesium (Prilosec 1 TM ) October 20, 2000 Larry Goldkind MD Division of Gastrointestinal and Coagulation Drug Products CDER, FDA.
NEUROPATHIC PAIN – OPTIMIZING PATIENT OUTCOME WITH COMBINATION THERAPY.
Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post- Polycythemia.
Seborrheic Dermatitis: What It Is and How to Treat It What is seborrheic dermatitis? Seborrheic dermatitis is a disease that causes flaking of the skin.
Our Experiences With Natural Natural Products As Potential Therapeutic Agents : Towards Safer & Cost Effective Therapy Dr. Mrs.Chanda Kulkarni. MBBS; MD;
Bepotastine Besilate Ophthalmic Solution 1.5% and Degree of Reduced Ocular Itching in a Conjunctival Allergen Challenge Test JI Williams 1, G Torkildsen.
Integrated Trial Results of Bepotastine Besilate Ophthalmic Solution 1.5% on Eyelid Swelling in a Clinical Model of Allergic Conjunctivitis TR McNamara.
Challenges of Non-Inferiority Trial Designs R. Sridhara, Ph.D.
Comparison of Bromfenac vs. Ketorolac During the Induction Phase of Treatment with Topical Cyclosporine for Dry Eye Patients Barry A. Schechter, MD Florida.
OBJECTIVE INTRODUCTION We previously presented results of an evaluation of the US sunscreen market (Nash et al. 2004). The present study continues this.
FDA Review of Clinical Data Agalsidase alfa for treatment of Fabry Disease Transkaryotic Therapies, Inc. FDA/Center for Biologics Evaluation and Research.
Alegre. almora. alonzo. amaro. amolenda. anacta. andal. ang. ang. ang. Dermatology Case 2:
Raymond F. Anton, MD for The COMBINE Study Research Group
1 OTC-TFM Monograph: Statistical Issues of Study Design and Analyses Thamban Valappil, Ph.D. Mathematical Statistician OPSS/OB/DBIII Nonprescription Drugs.
General properties of LAFTI strains in vitro Relatively good survival in conditions of the human GI tract (low pH, bile acids) Inhibit pathogenic bacteria.
Perspectives on Enhancing Consumer Outcomes with Topical Antifungals
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
1 Mohamed Alosh, Ph.D. Kathleen Fritsch, Ph.D. Shiowjen Lee, Ph.D. DBIII, OB, CDER, FDA Efficacy Evaluation in Acne Clinical Trials.
Scaly Dermatoses. Dandruff, seborrheic dermatitis, and psoriasis are chronic scaly dermatosis Dandruff inflammatory form and it has a substantial cosmetic.
Int J Clin Pract, December 2013, 67, 12,
INTRODUCTION As reported at the 2006 AAD Annual Meeting, patients with severe axillary sweating (including hyperhidrotics) struggle daily with the condition,
Statistical Considerations on NDA Sonia Castillo, Ph.D. Division of Biometrics 2 June 26, 2000.
Conclusions Sidney Cohen, MD Chairman, Department of Medicine Temple University School of Medicine Philadelphia, Pennsylvania Sidney Cohen, MD Chairman,
SP 2015 CP PROBABILITY & STATISTICS Observational Studies vs. Experiments Chapter 11.
Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.
Changes in Quality of Life and Disease- Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial.
Tetrabenazine (Xenazine ® ) Prestwick Pharmaceuticals NDA Peripheral and Central Nervous System Drugs Advisory Committee Meeting Beltsville, Maryland.
1 Clinical Overview Omeprazole Magnesium (Prilosec 1 TM ) June 21, 2002 Mark Avigan, MD CM Division of Gastrointestinal and Coagulation Drug Products CDER,
CDER / FDA1 Clinical Study Options for locally acting nasal suspension products Robert J. Meyer, MD Director, Div. Of Pulmonary and Allergy Drug Products.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.
Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adapalene Gel, 0.1%, as Maintenance Therapy for Acne.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
1 Statistical Issues in NDA Laura Lu, Ph.D FDA/CDER.
1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint
Pharmacological and Behavioral
Neal B, et al. Diabetes Care 2015;38:403–411
The Role of Sebaceous Gland Activity and Scalp Microfloral Metabolism in the Etiology of Seborrheic Dermatitis and Dandruff  Byung In Ro, Thomas L. Dawson 
Integrated Scoring Scale for Visual Evaluation of Heel Skin Condition
Volume 10, Issue 7, Pages (July 2018)
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Section 7: Aggressive vs moderate approach to lipid lowering
N3-378 Template 12/31/2018 7:52 PM 8 8.
The Role of Sebaceous Gland Activity and Scalp Microfloral Metabolism in the Etiology of Seborrheic Dermatitis and Dandruff  Byung In Ro, Thomas L. Dawson 
A Practical Guide to Scalp Disorders
LRC-CPPT and MRFIT Content Points:
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial  Tilo Biedermann,
EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE
Strategies in Pain Management
Ultragenyx Pharmaceutical Inc., Novato, CA
Major classes of drugs to reduce lipids
The efficacy and safety of omalizumab in pediatric allergic asthma
Product Pharmacology and Medical Actives in Achieving Therapeutic Benefits  James R. Schwartz  Journal of Investigative Dermatology Symposium Proceedings 
Vichy Dercos DS Anti-Dandruff Shampoo Protocol Analysis
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial  Alice Gottlieb, MD, PhD, John Sullivan,
Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.
Presentation transcript:

Overall Effectiveness of a Potentiatied 2% Micronized Platelet Pyrithione Zinc Shampoo Among Severe Dandruff/Seborrheic Dermatitis Sufferers INTRODUCTION Dandruff/seborrheic dermatitis of the scalp is characterized by flaking, irritation, itch, redness, and dryness. These conditions can be more severe when symptoms are heightened, more persistent, and/or do not respond to treatment. Previously we reported efficacy of micronized platelet PTZ can be potentiated in a shampoo with cosmetic excipients such as zinc carbonate to improve bioavailability of PTZ 1. Here, we report the effectiveness of a potentiated, 2% ZPT shampoo which provides strong symptom relief against a range of symptom severity (i.e., moderate to severe) and is effective at reducing Malassezia. The primary objective of this work was to assess the overall effectiveness of a potentiated 2% micronized platelet PTZ shampoo among severe dandruff/seborrheic dermatitis sufferers. HL Rocchetta, PhD, JR Schwartz, PhD, T Darcy, PhD, J Erb, K Grau, J Thomas, PhD, J Morgan, F Luo, PhD, M Copas The Procter & Gamble Company, Cincinnati, OH  The potentiated 2% micronized PTZ shampoo is effective at reducing dandruff/seborrheic dermatitis symptoms (i.e., flaking, itch and dryness) across a range of severities (moderate to severe).  In vitro and in vivo testing support the effectiveness of the potentiated 2% micronized PTZ shampoo at reducing Malassezia, the most effectively treated cause of dandruff/seborrheic dermatitis. Reference 1 J. R. Schwartz, Product pharmacology and medical actives in achieving therapeutic benefits. J. Invest. Dermatol. Symp. Proc., : p CONCLUSIONS RESULTS OBJECTIVE Clinical Studies Study A – 500 subjects participated in a dandruff/seborrheic dermatitis prevalence study. Endpoints – dermatologist graded Adherent Scalp Flaking Scores (ASFS) and self assessed symptom severity. Study B – 97 subjects participated in a 3 week, double-blinded, parallel design, placebo controlled, randomized clinical study. Subjects refrained from using any dandruff products 2 weeks prior to the treatment period (shampoo usage - at least 3X/week). Endpoints - dermatologist graded ASFS and self assessed symptom severity. Consumer Study 208 subjects participated in a single product, 2 week consumer test with self reported dandruff/seborrheic dermatitis symptoms. Post-usage consumers reported how well the product controlled symptoms. In Vitro and In Vivo Antifungal Testing In Vitro - Solution-based and zone of inhibition assays (ZOI) whereby product dilutions are tested for anti-Malassezia activity. In Vivo – Two week consumer usage test (shampoo usage 3X/week) whereby scalp swabs are taken, slides prepared/stained and Malassezia enumerated by fluorescent microscopy. METHODS Clinical Studies Pairwise comparisons of self assessed symptoms demonstrate that severe sufferers (based on ASFS), are statistically different (p≤0.05) than moderate and mild sufferers (Table 1). The potentiated 2% ZPT shampoo provided ASFS reductions to 90.1% of moderate and severe sufferers and 94.4% of severe sufferers (Table 2). This work was funded by P&G Beauty Self Assessment Dandruff/ Seborrheic Dermatitis Symptom Descriptors Severity of Flaking Severity of Scalp Itch Severity of Dry Scalp Mild (ASFS 16-24) Never Experienced67.8%36.9%40.7% Very Slight to Slight26.3%43.4%46.6% Moderate5.9%14.8%11.9% Somewhat Severe to Severe 0%4.9%0.85% Moderate (ASFS 25-34) Never Experienced42.8%19.3%21.4% Very Slight to Slight38.5%50%51.7% Moderate15.2%24%22.8% Somewhat Severe to Severe 3.5%6.7%4.2% Severe (ASFS 35-80) Never Experienced22.6%11.6%10.8% Very Slight to Slight49.5%50.5%46.2% Moderate17.2%15.8%21.5% Somewhat Severe to Severe 10.7%22.1%21.6% Percent of Subjects that Experienced ASFS Reductions from Baseline at Week 3 Dandruff/ Seborrheic Dermatitis Potentiated 2% ZPT Shampoo (n=71)Placebo Shampoo (n=25)p-values (Potentiated 2% ZPT vs. Placebo) Moderate & Severe (ASFS ≥ 24)90.1% (n=64) ASFS units* 64% (n=16) -3.3 ASFS units* p= p< Severe (ASFS ≥ 34) 94.4% (n=34) ASFS units* 78.6% (n=11) -8.6 ASFS units* p= p< Table 2. ASFS Response to the Potentiated 2% ZPT Shampoo (Study B). * LS Mean Change in ASFS from baseline at week 3 Table 3. Reduction in Dandruff Severity Following a Consumer Use Study. Symptom Descriptors How would you describe your dandruff severity before you tried this product? How would you describe your dandruff severity after 2 weeks of using this product? p-values Extremely Slight to Slight 50%89%p≤0.05 Moderate to More than Moderate 50%11%p≤0.05 Table 1. Mean Self Assessed Symptoms by ASFS Severity (Study A) Antifungal Assays In Vitro/In Vivo TestPotentiated 2% ZPT Shampoo Placebo Shampoo Solution-Based Growth Inhibition ppm>31.3 ppm ZOI (1:10 dilution)30.47 mm0 mm Mean In Vivo Log Malassezia reduction from baseline at week (n=20) * (n=14) * Mean of 9 historical studies In Vitro & In Vivo Antifungal Tests In vitro and in vivo testing show potentiated 2% ZPT shampoo to be effective against Malassezia (Table 4). Table 4. In Vitro and In Vivo Malassezia reductions. Consumer Study Following 2 weeks of consumer usage, the potentiated 2% ZPT shampoo reduced dandruff symptoms reported to be ‘moderate to more than moderate’ from 50% to 11%.